Your session is about to expire
← Back to Search
G207 for Brain Cancer
Study Summary
This trial is testing the safety of a new virus therapy, G207, for brain tumors. The therapy will be combined with a low dose of radiation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have recovered from side effects of my previous cancer treatments.My tumor is between 1.0 and 3.0 cm in size and can be operated on.I was diagnosed with or am being treated for encephalitis, a CNS infection, or multiple sclerosis recently.I've recovered from side effects of previous treatments and it's been over a week since my last dose, or over 3 months if it was viral therapy.My treatment needs to be delivered through the brain's ventricles due to tumor location.I had my last radiation treatment for the brain or whole body over 3 months ago, or for specific areas over 28 days ago.I received my last monoclonal antibody treatment over 21 days ago.My blood, kidney, and liver tests are within normal ranges.I had a bone marrow transplant using my own cells more than 3 months ago.I have given my written consent to participate.I do not have any other type of cancer.I had my last chemotherapy dose 3 weeks ago, or 6 weeks ago if it was nitrosurea.I am between 3 and 21 years old.I needed more steroids or took more than 2 mg of dexamethasone daily before a specific treatment.My cerebellar brain tumor is aggressive and has not responded to standard treatments.I am not taking any other cancer treatments or experimental drugs.I am not currently taking medication for herpes or any drugs that weaken my immune system, except dexamethasone or prednisone.I am HIV positive.I am under 16 with a Lansky score over 60, or 16 and older with a Karnofsky score over 60.My brain tumor affects 3 or more lobes.I do not have any infections or conditions that would prevent me from having surgery.
- Group 1: HSV G207
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still available slots for participation in this investigation?
"Affirmative. According to clinicaltrials.gov, this medical study which was initially posted on September 12th 2019 is seeking out 15 participants from one site as of July 28th 2022."
Could octogenarians potentially partake in this medical experiment?
"The qualifications for this research require that participants are between 3 and 18 years of age. In total, there are 687 studies conducted with patients in the specified age group while 4229 trials were completed with individuals over 65."
What criteria must be met for individuals to qualify as candidates in this research?
"This clinical trial is accepting 15 people with astrocytoma aged between 3 and 18 years old. To be eligible, applicants must meet certain criteria such as having pathologically proven malignant cerebellar brain tumor (including medulloblastoma, glioblastoma multiforme, giant cell glioblastoma etc.) which has progressed or recurred despite standard care including surgery, radiotherapy and/or chemotherapy; age greater than 36 months but less than 19 years; lesion size of 1.0 cm to a maximum of 3.0 cm in diameter that can be accessed surgically by MRI; fully recovered"
What is the magnitude of participants involved in this research endeavor?
"Affirmative. Per the information provided on clinicaltrials.gov, this medical trial is presently recruiting participants, beginning from September 12th 2019 and most recently updated on July 28th 2022. A total of 15 patients are sought for enrollment by one site."
Has the FDA given approval for G207 to be used therapeutically?
"The data collected on G207's safety and efficacy is limited, thus Power assigned a score of 1."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger